Italy Radiopharmaceuticals Market witnessing a CAGR of 9.7% from 2022 to 2032.

November 30, 2023 12:43 PM CET | By EIN Presswire
Follow us on Google News:

Radiopharmaceuticals are radioactive compounds made for both clinical analysis and healing functions particularly in nuclear medication.

PORTLAND, OREGON, UNITED STATES, November 30, 2023 / -- According to a Allied Reports study, the Italy Radiopharmaceuticals Market is estimated a revenue CAGR of 9.7%. The study analyzes the important strategies, drivers, competition, market dynamics, size, and important investment regions.

The geriatric population is increasing in Italy, which is driving the demand for radiopharmaceuticals in the country. The increasing number of aged people increases more chances for them to suffer from chronic illness such as cancer cells, mental deterioration as well as heart diseases. Therefore, they need radiopharmaceuticals for clinical diagnosis treatment of such conditions.

Request Sample Copy of the Report:

The radiopharmaceuticals market growth was decreased during the lockdown period owing to disruptions to the production and supply of radiopharmaceuticals to nuclear medicine department.

Research Methodology

The research operandi of the global Radiopharmaceuticals Market includes significant primary as well as secondary research. When the primary methodology encompasses widespread discussion with a plethora of valued participants, the secondary research involves a substantial amount of product/service descriptions. Furthermore, several government sites, industry bulletins, and press releases have also been properly examined to bring forth high-value industry insights.

The global radiopharmaceuticals market is driven by factors such as rise in prevalence of cancer, cardiovascular and neurological disease, increase in demand for medical imaging, and increase in number of product approval for radiopharmaceuticals. However, side effect associated with radiopharmaceuticals is hampering the radiopharmaceuticals market growth. On the contrary, presence of radiopharmaceutical industry and increase in R&D activities for radiopharmaceuticals are expected to offer remunerative opportunities for expansion of the italy radiopharmaceuticals market during the forecast period.

Market Segmentation:

By End User:

Hospitals and clinics
Medical Imaging centers

By Radioisotope:

Iodine I
Gallium 68
Technetium 99m
Fluorine 18

By Application:


By Type:


Request for Customization (Get a 20% Discount):

Competitive Landscape:

Curium Pharma.
Alseres Pharmaceuticals
Jubilant DraxImage
IBA Molecular
Piramal Imaging
Bracco Imaging

Buy this Premium Research Report (Get a 20% Discount):

Key Questions Answered in the Intelligent Study

What is the market size and growth rate of the global and regional market by various segments?
What is the market size and growth rate of the market for selective countries?
Which region or sub-segment is expected to drive the market in the forecast period?
What Factors are estimated to drive and restrain the market growth?
What are the key technological and market trends shaping the market?
What are the key opportunities in the market?
What are the key companies operating in the market?
Which company accounted for the highest market share?

Why Choose Allied Market Research?

Industries' Best Analysts
Exclusive Product Offerings
Customer Research Services
Dynamics Research Methodology
Comprehensive Reports
Latest Technological Advancements
Value Chain Analysis
Future Market Opportunities
Market Growth Dynamics
Quality Assurance
Post-sales Support
Continuous Report Update

Market Dynamics and Transformations

Economic Downturn Analysis: Impact of Recession in 2023
Pandemic's Influence: Impact of Covid-19 Pandemic
Market Evolution: Recent Developments in the Market with Key Players Announcements

Browse more latest healthcare reports (Get a 20% Discount):

Radiopharmaceuticals Market by Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), by Application (Cancer, Cardiology, Others), by Type (Diagnostic, Therapeutic), by End User (Hospitals and clinics, Medical Imaging centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Brazil Radiopharmaceuticals Market by Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), by Application (Cancer, Cardiology, Others), by Type (Diagnostic, Therapeutic), by End User (Hospitals and clinics, Medical Imaging centers, Others): Opportunity Analysis and Industry Forecast, 2023-2032

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+ +1 800-792-5285
email us here
Visit us on social media:


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Top ASX Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK